Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Part B Prior Auth Policy …
    Ask Trek AI about this page
    Currentpriority healthPolicy N/A

    Medicare Part B Prior Authorization and Step Therapy Criteria (July 2026)

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization and step therapy requirements for Medicare Part B drugs administered by providers under Priority Health Medicare; affects providers submitting PA/ST requests and billing for Part B drugs.

    Policy Summary
    Payerpriority health
    PolicyMedicare Part B Prior Authorization and Step Therapy Criteria (July 2026)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit a Medicare Part B drug request form or Web Form with required medical records to obtain prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Part BBenefit
    1–2 yrsTypical duration
    AppliedStep therapy
    4Distinct products
    Yes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Part B ST designation

    Policy Header & Overview

    Key definitions
    Part B drugOutpatient prescription drugs and biologics administered by infusion or injection, furnished incident to a provider service and not usually self-administered.
    Medically accepted indication (MAI)Indication as defined by CMS; used to evaluate Part B coverage when no NCD/LCD/LCA exists (review includes compendia, literature, accepted standards).
    Biosimilar / InterchangeableA product highly similar to a reference biologic with no clinically meaningful differences; FDA may designate interchangeability allowing substitution.
    Hypogonadism (male) / Morning total testosteroneDiagnosis requires two separate morning total testosterone measurements below normal (commonly <300 ng/dL) plus signs/symptoms of deficiency.
    anti-AAVrh74 titer (Elevidys selection)Anti-AAVrh74 total binding antibody titer must be <1:400 for Elevidys eligibility.

    Coverage Criteria (Product-level Initial & Continuation)

    Actemra (tocilizumab) — Initial/General criteria

    Covered when ALL of the following are met

    Actemra group coverage: 1) Use is for a medically accepted indication not otherwise excluded; 2) Must not be used in combination with other biologic drugs, Otezla, or Janus Kinase Inhibitors (JAKis); 3) Intravenous Actemra is not approved for systemic sclerosis–associated interstitial lung disease (SSc-ILD); 4) Prescriber is a specialist or has consulted with a specialist for the condition being treated; 5) Medical records supporting the request are provided, including documentation of prior therapies and responses to treatment; 6) Step therapy: patient has tried Tyenne prior to approval;

    Coverage duration 2 years; dose per FDA labeling or accepted standards.

    Adakveo — Initial/General criteria

    Covered when ALL of the following are met

    Adakveo group coverage: 1) Use is for a medically accepted indication not otherwise excluded; 2) Medical records supporting the request are provided; 3) Step therapy: patient has tried hydroxyurea for 6 months or has documented intolerance/contraindication to hydroxyurea prior to approval;

    Coverage duration 2 years; dose per FDA labeling or accepted standards.

    Initial Therapy Criteria (Extracted per Product)

    Reauthorization / Continuation Criteria

    Step Therapy Requirements (Prior Trials Required)

    ProductRequired prior agent(s) (step therapy)Notes / trial duration / exceptions
    Adakveo (crizanlizumab)Hydroxyurea (trial 6 months)Must document 6‑month hydroxyurea trial or intolerance/contraindication; coverage duration 2 years; submit Medicare Part B drug request form.
    Alyglo (IVIG)Two preferred IVIG products (examples: Gammagard Liquid, Gamunex‑C, Privigen)Part B vs Part D determination required; must try two preferred IVIGs prior to Part B IVIG coverage; provide medical records.
    Alymsys (bevacizumab biosimilar)Mvasi AND ZirabevMust try both biosimilars (Mvasi and Zirabev) prior to Avastin (J9035); criteria applied consistent with LCD L37205; coverage up to 1 year.
    Avastin (bevacizumab) — J9035 chemotherapyMvasi AND ZirabevChemotherapy J9035 only; must document trials of Mvasi and Zirabev before Avastin; coverage duration up to 1 year; use Oncology drug request form.
    Aveed (testosterone undecanoate)Generic intramuscular testosterone (cypionate or enanthate) AND generic topical testosteroneFor hypogonadism/gender dysphoria pathways: must document trials/failures of generic IM and topical testosterone, two morning total testosterone measurements on separate days <300 ng/dL (or below lab reference), and clinical signs; coverage 2 years.
    Azmiro (testosterone formulation)Generic testosterone cypionate trialPrior trial and failure of generic testosterone cypionate required; must supply two morning total testosterone measurements <300 ng/dL and clinical signs; coverage 2 years.
    Beizray / Beizray‑Albumin (docetaxel formulations)Generic docetaxel (Taxotere, HCPCS J9171)Must first try generic docetaxel (J9171) prior to Beizray/Beizray‑Albumin; provide medical records; coverage duration 1 year.
    Boruzu (bortezomib)Generic bortezomib injectable (e.g., HCPCS J9049 or J9041)Step therapy requires trial of a generic bortezomib product prior to Boruzu; provide prior‑therapy documentation; coverage up to 1 year.
    Aukelso (denosumab biosimilar)Wyost, Xtrenbo, AND BilprevdaMust try all three prior to Aukelso; biosimilar provisionally interchangeable with Xgeva; coverage up to 2 years.
    Bomyntra (denosumab biosimilar)Wyost, Xtrenbo, AND BilprevdaMust first try Wyost, Xtrenbo, and Bilprevda before Bomyntra; provide medical records; coverage up to 2 years.
    Bosaya (denosumab biosimilar)Jubbonti, Enoby, AND BildyosMust first try listed preferred denosumab/alternatives prior to Bosaya; provide documentation; coverage per FDA labeling.
    Cimzia (certolizumab)Failure of TWO agents (e.g., preferred adalimumab product AND another listed agent such as Rinvoq, Skyrizi, Tyenne, Cosentyx, Otezla, Xeljanz/XR, Yesintek/Selaradi or Enbrel)Step therapy requires failure/intolerance of two specified agents; prescriber specialist or consultation; coverage duration 2 years.
    Cinqair (reslizumab)ICS/LABA plus 1 other controller (prior controller therapy) — and biomarker criteriaFor severe eosinophilic asthma: eosinophils ≥150 cells/µL at start OR ≥300 cells/µL in prior 12 months; must have tried appropriate inhaled controller regimen; provide weight and records.
    Cinryze (C1‑esterase inhibitor)HaegardaMust first try Haegarda before Cinryze; provide medical records documenting prior therapies and responses; coverage duration 2 years.
    Conexxence (C1‑esterase reference biosimilar)Jubbonti, Enoby, AND BildyosMust first try Jubbonti, Enoby, and Bildyos prior to Conexxence; provide prior‑therapy documentation; coverage up to 2 years.
    Cosentyx IV (secukinumab IV)Avsola OR Renflexis OR Simponi AriaMust first try Avsola, Renflexis, or Simponi Aria prior to Cosentyx IV; not to be used in combination with other biologics, Otezla, or JAK inhibitors; prescriber specialist; coverage 2 years.
    Docivyx (docetaxel)Generic docetaxel (Taxotere, J9171)Must first try generic docetaxel (J9171) prior to Docivyx; submit Medicare Part B (Non‑Oncology) drug request form; coverage duration 1 year.
    Durysta (bimatoprost implant)Two topical prostaglandin analogs (latanoprost, bimatoprost, travoprost)Must try TWO topical prostaglandin analogs prior to Durysta implant; provide documentation of trials and responses; dosing per FDA labeling.
    Emblaveo (aztreonam‑avibactam)All other generic susceptible antibiotics per culture/sensitivity (or empiric guidance)Designated Part B Step Therapy drug; must try other appropriate antibiotics per culture/sensitivity; prescriber infectious disease specialist or consult; approval limited to 6 months.
    Enjaymo (sutimlimab)Rituximab‑containing regimen (documented trial and failure)Document trial and failure of a rituximab‑containing regimen prior to Enjaymo; provide transfusion history, baseline labs, weight; initial 6 months, reauth 12 months with documented benefit.
    Entyvio (vedolizumab)Avsola OR RenflexisMust first try Avsola or Renflexis prior to Entyvio; provide medical records documenting prior therapies and responses; not used with other biologics/Otezla/JAK inhibitors; initial 1 year, reauth 2 years.
    Epogen (epoetin alfa) — non‑ESRD Part B requestsProcrit AND RetacritNon‑ESRD Part B requests must first try Procrit and Retacrit per LCD L34633; provide documentation; coverage up to 2 years.
    Erzofri (paliperidone long‑acting)Invega Sustenna OR Invega Trinza OR Invega HayferaMust first try one of the specified Invega products prior to Erzofri; step therapy applied per guidance.
    Evenity (romosozumab)Oral bisphosphonate (alendronate, risedronate, ibandronate) AND either zoledronic acid or Jubbonti — OR meet very high fracture risk criteriaMust meet one pathway: prior bisphosphonate plus zoledronic acid/Jubbonti failure or very high fracture risk (T‑score thresholds); cumulative use limited to 12 months lifetime; prescriber endocrinologist; coverage 12 months per lifetime.
    Evkeeza (evinacumab)Repatha (prior trial) — except children 5–9 years where trial not requiredMust first try Repatha prior to Evkeeza (trial not required in children 5–9 yrs); provide medical records documenting prior therapies and responses; coverage 2 years.
    Casgevy (gene therapy)N/A (one‑time gene therapy) — must document prior standard therapies such as hydroxyurea or alternatives for SCD; transfusion history for beta thalassemiaRequires comprehensive documentation (genotype confirmation for SCD or transfusion dependence for beta thalassemia), prior therapy history, organ function and HSCT eligibility; limited to one lifetime dose; authorization 6 months; prior HSCT or prior gene therapy excludes coverage.
    Prior Authorization

    Submit Medicare Part B PA form with complete supporting records

    Submit prior authorization using the Medicare Part B (Non‑Oncology) drug request form or the applicable Web Form (Oncology form for chemotherapeutics). Include completed request form fields (drug, dose, frequency, place of administration) and attach supporting medical records documenting diagnosis, prior therapies and responses, required labs/diagnostic tests, prescriber specialty/consultation when specified, and any weight or transfusion history requested by the product-specific criteria. Coverage durations and product-specific prior‑therapy/step requirements are determined from the PA review; follow product nodes for exact duration and step edits (examples: Adakveo — 6‑month hydroxyurea trial; Aukelso — trials of Wyost, Xtrenbo, AND Bilprevda; Avastin J9035 — must first try Mvasi AND Zirabev).

    • Use the Medicare Part B drug request form or Web Form to streamline review and determine Part B vs Part D responsibility [[chunk 121],[chunk 122],[chunk 145]].
    • Attach supporting medical records: diagnosis, prior therapies and responses, baseline and follow‑up data, required labs/diagnostics, patient weight or transfusion history when requested [[chunk 122],[chunk 173],[chunk 179]].
    • Follow product‑specific PA rules: Adakveo requires documentation of a 6‑month hydroxyurea trial or intolerance/contraindication; Aukelso requires prior trials of Wyost, Xtrenbo, AND Bilprevda; Avastin (J9035) requires trials of Mvasi AND Zirabev per LCD L37205 [[chunk 19],[chunk 123],[chunk 124],[chunk 45]].
    • Observe PA coverage durations and prescriber restrictions indicated per product (typical initial durations: 1 year for many agents; some 2 years; some gene therapies/implants have unique limits) and include specialist attestation when required [[chunk 127],[chunk 131],[chunk 133],[chunk 136],[chunk 140]].

    Coding & Billing (HCPCS/CPT/NDC references)

    Covered HCPCS Codes - AvastinHCPCSCovered
    J9035Bevacizumab, chemotherapy drug code (Avastin) — chemotherapy (J9035) only
    Neutral / Referenced HCPCS for Prior Trial - DocetaxelHCPCS
    J9171Docetaxel (generic) — referenced comparator HCPCS (Taxotere, J9171)
    J9049Generic bortezomib injectable — example HCPCS referenced for prior trial (J9049)
    J9041Generic bortezomib injectable — example HCPCS referenced for prior trial (J9041)
    Neutral — Product Name Entries (no explicit HCPCS provided)mixed
    BivigamAffected product name listed (Bivigam)
    BkemvAffected product name listed (Bkemv)
    Neutral — Benlystamixed
    BenlystaBelimumab product referenced for SLE and Lupus Nephritis (no explicit CPT/HCPCS code listed)
    Neutral — Cimzia product listingsmixed
    CIMZIA 2X200 MG/ML SYRINGE KIT 2X200MG SYR/BOXProduct affected (text listing)
    Cimzia Powder for ReconstProduct affected (text listing)
    Cimzia Starter KitProduct affected (text listing)
    Neutral — Cinqair product listingmixed
    CinqairProduct affected (text listing)
    Neutral — Docivyx referenced comparator HCPCSHCPCS
    J9171Docetaxel (Taxotere) — generic comparator HCPCS referenced as required prior agent (J9171)
    Neutral — Beizray docetaxel comparatorHCPCS
    J9171Docetaxel (Taxotere) — referenced as required prior agent before Beizray / Beizray kit (J9171)
    Neutral — Azmiro (no explicit billing codes)mixed
    No codes listed
    Required numeric clinical thresholds and lab values
    Severe AAT deficiency (Aralast/Aralast NP)Serum AAT < 11 micromol/L (≈57 mg/dL by nephelometry; alternative measures: 80 mg/dL by radial immunodiffusion or 50 mg/dL nephelometry noted).
    Morning total testosterone (Azmiro/Aveed)Two pre-treatment morning total testosterone measurements on separate days <300 ng/dL (or below laboratory reference) required for hypogonadism pathway.
    SELENA-SLEDAI and serology (Benlysta)SELENA-SLEDAI score ≥6 AND either anti-dsDNA >30 IU/mL or ANA titer >1:80 required for initial SLE coverage.
    Eosinophil threshold (Cinqair / severe eosinophilic asthma)>=150 cells/mcL at therapy start OR >=300 cells/mcL in the prior 12 months.
    Transfusion dependence (Casgevy — beta thalassemia)>=100 mL/kg/year OR >=10 units/year of packed RBCs in the previous 2 years.

    Provider Actions, Prior Authorization Process & Denial Triggers

    Prior Authorization

    Submit Medicare Part B drug request form with complete documentation

    Complete and submit the appropriate Medicare Part B drug prior authorization request form (Oncology or Non‑Oncology) or the web form and include dose, frequency, place of administration, and supporting medical records to support the request.

    • Use the Medicare Part B (Oncology or Non‑Oncology) drug request form or Web Form to streamline review.
    • Include dose, frequency, place of administration, and supporting medical records documenting prior therapies and clinical response.
    Documentation Required

    Include product‑specific documentation with PA submissions (Azmiro, Beizray, Benlysta, Cimzia, Cinqair)

    Provide the product‑specific supporting documentation requested in the policy when submitting the prior authorization for Azmiro, Beizray, Benlysta, Cimzia, and Cinqair — failure to include these items will delay or risk denial.

    • Azmiro: medical records showing trial and failure of generic testosterone cypionate and two separate morning total testosterone measurements <300 ng/dL, plus clinical signs of testosterone deficiency and birth‑sex documentation.

    Quantity Limits, Dose & Site-of-Care Notes

    Quantity limits and dosing rules
    Dose approvalsDoses are approved per FDA‑approved labeling or within accepted standards of medical practice.
    Casgevy quantity limitOne lifetime dose (limit = 1 dose); authorization duration 6 months.
    Denosumab biosimilars (Bomyntra/Bosaya) dosingDose per FDA labeling or within accepted standards; coverage durations up to 2 years where specified.
    Product-specific limits (Encelto)Encelto: approval limited to 6 months and one implant per affected eye lifetime.
    Typical coverage duration guidanceInitial and reauthorization durations vary by product (commonly 1 year initial; many reauthorizations up to 2 years).

    Biosimilar & Interchangeable Product Guidance

    Billing Rule

    Biosimilar substitution and biosimilar-first step edits — trials of biosimilars/generics required where specified

    Where the FDA has approved biosimilars, Priority Health expects providers to document trials of biosimilars or generics per product‑specific step edits (examples: Avtozma/Actemra biosimilars; Mvasi and Zirabev tried before Avastin; Avsola or Renflexis prior to Entyvio).

    • Avtozma (tocilizumab biosimilar) and other tocilizumab biosimilars are supported as substitutes for Actemra per FDA guidance.
    • Avastin (J9035) chemotherapy requires prior trials of Mvasi AND Zirabev before Avastin.
    • Entyvio requires trial of Avsola OR Renflexis prior to approval.

    Key Clinical Thresholds & Eligibility Values

    Key numeric thresholds for eligibility and reauthorization
    AAT severe deficiency thresholdSerum AAT < 11 micromol/L (≈57 mg/dL nephelometry; 80 mg/dL radial immunodiffusion or 50 mg/dL nephelometry alternative cited).
    Morning total testosterone for eligibilityTwo morning total testosterone measurements <300 ng/dL on separate days (or below lab reference) required for hypogonadism eligibility and reauthorization checks.
    SELENA‑SLEDAI and autoantibodiesSELENA‑SLEDAI ≥6 plus anti‑dsDNA >30 IU/mL OR ANA >1:80 required for Benlysta initial eligibility and for reauthorization documentation of disease activity.
    Eosinophil thresholds for biologic asthma agents>=150 cells/mcL at therapy start OR >=300 cells/mcL in prior 12 months required for Cinqair and related reauthorization assessments.
    Transfusion dependence for Casgevy (beta thalassemia)>=100 mL/kg/year OR >=10 units/year pRBC in prior 2 years required to qualify as transfusion‑dependent.

    Policy Revision History

    2026-07-01policy_effective_dateLatest

    Policy effective date set to 2026-07-01.

    2026-07-01last_review

    Policy last reviewed on 2026-07-01.

    Policy Summary
    Payerpriority health
    PolicyMedicare Part B Prior Authorization and Step Therapy Criteria (July 2026)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit a Medicare Part B drug request form or Web Form with required medical records to obtain prior authorization.
    SourceLink
    On This Page
    Policy Header & OverviewCoverage Criteria (Product-level Initial & Continuation)Initial Therapy Criteria (Extracted per Product)Reauthorization / Continuation CriteriaStep Therapy Requirements (Prior Trials Required)Coding & Billing (HCPCS/CPT/NDC references)Provider Actions, Prior Authorization Process & Denial TriggersQuantity Limits, Dose & Site-of-Care NotesBiosimilar & Interchangeable Product GuidanceKey Clinical Thresholds & Eligibility ValuesPolicy Revision History

    Adakveo - Initial Authorization

    Covered when ALL of the following are met:

    Adakveo initial criteria: 1) Indication: medically accepted indication for Adakveo; 2) Documentation: medical records supporting the request provided; 3) Step therapy: documented trial and failure of hydroxyurea for 6 months (or documented intolerance/contraindication allowing exception); 4) Dose and administration consistent with FDA-approved labeling or accepted standards of care.

    Coverage duration 2 years.

    Adzynma - Initial/Authorization and Reauthorization criteria

    Covered when ALL of the following are met:

    Adzynma initial criteria: Initial requests require genetic testing confirming diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP) AND ADAMTS13 activity <10%; medical records including current weight for dosing must be provided; prescriber is or has consulted with a specialist. Initial prophylactic dosing frequency must be every 2 weeks (may be adjusted to once weekly with documentation).

    Initial coverage duration 12 months.

    Adzynma reauthorization criteria: Reauthorization requires medical records demonstrating beneficial clinical response (e.g., decreased acute/subacute TTP events, improved platelet counts, decreased hemolytic episodes).

    Reauthorization duration 12 months.

    Alhemo - Initial Authorization and Reauthorization

    Covered when ALL of the following are met:

    Alhemo initial criteria - Hemophilia A: Alhemo is used for routine prophylaxis to prevent or reduce bleeding episodes in hemophilia A: patient has hemophilia A (with or without factor VIII inhibitors) AND has tried and failed Hemlibra; patient is ≥12 years of age; prescribed by or in consultation with a hematologist or specialist; medical records provided.

    Initial coverage duration 12 months.

    Alhemo initial criteria - Hemophilia B: Alhemo is used for routine prophylaxis to prevent or reduce bleeding episodes in hemophilia B: patient has hemophilia B (with or without factor IX inhibitors); patient is ≥12 years of age; prescribed by or in consultation with a hematologist or specialist; medical records provided.

    Initial coverage duration 12 months.

    Alhemo reauthorization criteria: For reauthorization, patient continues routine prophylaxis AND documentation of clinical benefit provided (e.g., fewer bleeding episodes, reduced use of replacement therapy or bypassing agents).

    Reauthorization duration 12 months.

    Alyglo — Initial Coverage Criteria

    Alyglo (immune globulin intravenous, human-stwk) — Covered when ALL of the following are met:

    Alyglo all criteria: 1) Use is for a medically accepted indication not otherwise excluded; 2) Medical records supporting the request are provided, including documentation of prior therapies and responses; 3) For Part B benefit determinations, patient has tried two preferred IVIG products (examples: Gammagard Liquid, Gamunex-C, Privigen) unless clinically contraindicated; 4) Submit the Medicare Part B (Non‑Oncology) drug request form or Web Form as applicable;

    Coverage duration 2 years; dose per FDA labeling or accepted standards; refers to LCD L34771 for IVIG determinations.

    Alymsys — Initial Coverage Criteria

    Alymsys (bevacizumab biosimilar) — Covered when ALL of the following are met:

    Alymsys all criteria: 1) Use is for a medically accepted indication not otherwise excluded; 2) Medical records supporting the request are provided, including documentation of prior therapies and responses; 3) Step therapy: patient has tried Mvasi AND Zirabev prior to approval; 4) Criteria applied consistent with LCD L37205 for chemotherapy drugs;

    Coverage duration up to 1 year; dose per FDA labeling or accepted standards.

    Amvuttra — Indication-specific Initial Coverage Criteria

    Amvuttra (vutrisiran) — Covered when ALL of the following are met by indication:

    Amvuttra indications: Indication A (hATTR‑PN): patient has a pathogenic TTR mutation AND baseline polyneuropathy disability (PND) score ≤ IIIb AND clinical signs/symptoms of neuropathy; Indication B (ATTR‑CM): patient has NYHA class I–III heart failure with current manifestations or prior HF hospitalization AND imaging (ECHO or CMR) demonstrating cardiac involvement AND diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging (99mTc‑PYP/DPD/HMDP) (if radionuclide imaging used, documentation of Grade 2 or 3 cardiac uptake required) AND patient has tried and failed tafamidis (Vyndamax or Vyndaqel).

    Age ≥18 years; do not approve if primary (light‑chain) amyloidosis present; initial coverage duration 1 year; do not co‑administer with TTR stabilizers or TTR‑lowering agents.

    Amvuttra - Initial/Authorization and Reauthorization criteria

    Amvuttra — Reauthorization criteria

    Amvuttra reauth: For reauthorization of hATTR‑PN: documentation demonstrating a positive clinical response compared to baseline (examples: improved neuropathy symptoms, motor function, quality of life, slowing of disease progression). For reauthorization of ATTR‑CM: documentation demonstrating a positive clinical response compared to baseline (examples: reduced cardiovascular‑related hospitalizations, improved function, improved quality of life).clinical improvement vs baseline

    Reauthorization duration 1 year.

    Amvuttra — Reauthorization criteria and requirement to demonstrate clinical benefit compared to baseline

    Reauthorization covered when documentation demonstrates clinical benefit compared to baseline

    Amvuttra reauthorization: Documentation demonstrating a positive clinical response to Amvuttra compared to baseline must be provided (examples: improved neuropathy symptoms, motor function, quality of life, or reduced cardiovascular events as applicable).clinical improvement vs baseline

    Reauthorization duration 1 year.

    Aralast NP — Initial Therapy

    Covered when ALL of the following are met

    Aralast NP initial approval: 1) Diagnosis of alpha‑1‑antitrypsin deficiency with phenotype PiZZ, PiZ (null), or Pi(null,null) OR phenotypes associated with reduced serum AAT; AND 2) Serum AAT less than 11 micromoles per liter (protective threshold) AND 3) Patient has symptomatic emphysema; AND 4) Medical records supporting the request provided.AAT < 11 micromol/L

    Coverage duration 2 years; dose per FDA labeling.

    Asceniv — Initial Therapy / Step Therapy

    Covered when documentation supports medically accepted indication and step therapy met for Part B determinations

    Asceniv (IVIG) Part B criteria: 1) Use is for a medically accepted indication not otherwise excluded; 2) Medical records supporting the request provided, including documentation of prior therapies and responses; 3) For Part B benefit determinations, patient has tried two preferred IVIG products (e.g., Gammagard Liquid, Gamunex‑C, Privigen) unless contraindicated;trial of 2 preferred IVIGs

    Coverage duration 2 years; dose per FDA labeling; refer to LCD L34771.

    Aukelso — Step Therapy and Coverage Criteria

    Covered when ALL of the following are met

    Aukelso step therapy: 1) Medical records supporting the request provided; AND 2) Step therapy: patient has tried Wyost, Xtrenbo, AND Bilprevda prior to Aukelso approval;prior trials of 3 products

    Coverage duration up to 2 years; dose per FDA labeling.

    Avastin (J9035) — Coverage Criteria (chemotherapy context)

    Covered when ALL of the following are met:

    Avastin chemotherapy criteria: 1) Medical records documenting prior therapies and responses provided; 2) Step therapy: patient has tried Mvasi AND Zirabev prior to Avastin (J9035) approval; 3) Criteria applied consistent with LCD L37205; 4) Dose and use consistent with FDA‑approved oncology indications.

    Coverage duration up to 1 year; chemotherapy (J9035) only.

    Aveed — Coverage Criteria with separate branches for hypogonadism and gender dysphoria

    Covered when ALL of the following are met (separate branches for hypogonadism and gender dysphoria):

    Indication branches: Branch A — Hypogonadism: must have trial and failure of generic intramuscular testosterone (cypionate or enanthate) AND trial and failure of a generic topical testosterone AND two pre‑treatment morning total testosterone measurements on separate days <300 ng/dL (or below lab reference) AND clinical signs/symptoms consistent with testosterone deficiency other than erectile dysfunction or decreased libido AND patient assigned male at birth. Branch B — Gender dysphoria (masculinizing GAHT): must have trial and failure of generic intramuscular testosterone AND trial and failure of generic topical testosterone.two morning testosterone <300 ng/dL for hypogonadism branch

    Coverage duration 2 years; dose per FDA labeling or accepted standards.

    Avgemsi — Coverage Criteria

    Covered when ALL of the following are met:

    Avgemsi criteria: 1) Medical records documenting prior therapies and responses provided; 2) Step therapy: patient has tried generic gemcitabine injection (Gemzar) prior to Avgemsi; 3) Dose and administration consistent with FDA labeling or accepted standards.

    Coverage duration up to 1 year.

    Avtozma/Other product-specific initial coverage criteria grouped here

    Covered when ALL of the following are met for each listed product

    Documentation: Medical records supporting the request are provided, including documentation of prior therapies and responses to treatment specific to the requested product.

    Use Medicare Part B (Oncology or Non‑Oncology) drug request form or Web Form as applicable.

    Submission: Request submitted via the Medicare Part B drug request form or Web Form to streamline review.
    Step Therapy: Patient must have tried the specified first‑line/generic comparator prior to approval (examples: generic gemcitabine for Avgemsi; generic etoposide for Avopef; Tyenne before Avtozma; generic pemetrexed for Axtle).

    Exact prior agent depends on product.

    Coverage Duration: Treatment approved for the specified product duration (commonly 1 year; some biosimilars/agents up to 2 years).

    Dose per FDA labeling or accepted standards.

    Azmiro — Covered when ALL of the following are met

    Covered for hypogonadism or gender dysphoria when required documentation is supplied and step therapy is met.

    Azmiro initial coverage criteria: 1) Trial and failure of generic testosterone cypionate (inability to improve symptoms or testosterone levels) documented; 2) Two pre‑treatment morning serum total testosterone measurements on separate days <300 ng/dL (or below lab reference) documented; 3) Clinical signs/symptoms consistent with testosterone deficiency other than erectile dysfunction or decreased libido; 4) For hypogonadism pathway, patient was assigned male at birth; 5) Medical records supporting the request provided.two morning testosterone <300 ng/dL

    Coverage duration 2 years.

    Beizray / Beizray-Albumin — Covered when ALL of the following are met

    Covered for medically accepted indications when prior trial of generic docetaxel is documented.

    Beizray initial coverage criteria: 1) Medical records documenting prior therapies and responses provided; 2) Step therapy: trial and failure of generic docetaxel (Taxotere, HCPCS J9171) prior to Beizray or Beizray‑Albumin;

    Coverage duration 1 year; dose per FDA labeling.

    Benlysta IV — SLE and Lupus Nephritis initial coverage and reauthorization criteria

    Covered for SLE or lupus nephritis with required disease activity and serologic/biopsy confirmation.

    Benlysta SLE initial coverage: 1) Medical records documenting prior therapies and responses provided; 2) SELENA‑SLEDAI score ≥ 6 prior to starting Benlysta; 3) Either anti‑dsDNA antibody >30 IU/mL OR ANA titer >1:80; 4) Patient is receiving standard‑of‑care therapy per guidelines (e.g., two of steroid, immunosuppressant, hydroxychloroquine for at least 12 weeks each); 5) Prescriber is a specialist or has consulted with a specialist.SELENA‑SLEDAI ≥6; anti‑dsDNA >30 IU/mL or ANA >1:80

    Initial coverage duration 1 year.

    Benlysta lupus nephritis initial coverage: 1) Confirmed diagnosis of SLE AND kidney biopsy confirming class 3, 4 and/or 5 disease; 2) Receiving standard therapy for lupus nephritis (e.g., mycophenolate or azathioprine plus steroid); 3) Medical records documenting prior therapies and responses provided; 4) Prescriber is a specialist or has consulted with a specialist.kidney biopsy class 3, 4, and/or 5

    Initial coverage duration 1 year; reauthorization requires improved or stable eGFR.

    Benlysta reauthorization: Evidence of clinical improvement since starting Benlysta (for SLE) OR evidence of clinical improvement including improved or stable eGFR (for lupus nephritis) must be provided for reauthorization.clinical improvement or stable/improved eGFR

    Reauthorization duration 2 years.

    Bivigam (IVIG) — Part B Coverage

    Covered when ALL of the following are met for Part B‑designated indications:

    Bivigam Part B coverage: 1) Medical records supporting the request are provided, including documentation of prior therapies and responses; 2) For requests determined to be Part B, patient has tried two preferred IVIG products (e.g., Gammagard Liquid, Gamunex‑C, Privigen) unless contraindicated; 3) Dose and administration consistent with FDA labeling or accepted standards of practice.trial of two preferred IVIG products

    Coverage duration 2 years.

    Bkemv, Bkemv-Albumin and related product-specific initial coverage criteria

    Covered when ALL of the following are met (by indication):

    Bkemv NMOSD initial coverage: 1) Patient is anti‑AQP4 antibody positive; AND 2) Patient has tried and failed Epysqli (inadequate response or intolerance); AND 3) Bkemv will not be used in combination with Uplizna, Enspryng, or other NMOSD medications; AND 4) Medical records supporting the request provided.AQP4 antibody positive; prior Epysqli failure

    Initial coverage 1 year; reauthorization 2 years with decreased relapse rate evidence required.

    Bkemv PNH initial coverage: 1) Diagnosis of PNH confirmed by flow cytometry; AND 2) Hemolysis‑associated symptoms present; AND 3) Patient has tried and failed Epysqli; AND 4) Bkemv will not be used in combination with other complement drugs (Fabhalta, Ultomiris, Empaveli); AND 5) Medical records provided.flow cytometry confirmation; prior Epysqli failure

    Reauthorization requires improvement in symptoms and hemoglobin/hemolysis measures.

    Bkemv aHUS initial coverage: 1) Shiga‑toxin HUS and TTP ruled out; AND 2) Patient has tried and failed Epysqli; AND 3) Medical records provided.exclusion of other causes; prior Epijkstra failure

    Reauthorization requires decreased signs of TMA.

    Bkemv Myasthenia Gravis initial coverage: 1) Baseline MG‑ADL score ≥6; AND 2) Diagnosis of generalized MG that is AChR‑Ab positive; AND 3) Tried and failed Epijkstra AND tried Vyvgart or Vyvgart Hytrulo with intolerance or inadequate response; AND 4) Bkemv will not be used in combination with similar MG therapies (chronic IVIG, Vyvgart, Ultomiris, Rystiggo, Zilbrysq); AND 5) Medical records provided.MG‑ADL ≥6; AChR‑Ab positive; prior therapy failures

    Reauthorization requires documented improvement in MG‑ADL from baseline.

    Bomyntra — Initial Therapy

    Bomyntra covered when ALL of the following are met:

    Bomyntra criteria: 1) Medical records supporting the request provided including documentation of prior therapies and responses; AND 2) Step therapy: patient has tried Wyost, Xtrenbo, AND Bilprevda prior to Bomyntra;

    Coverage duration up to 2 years; dose per FDA labeling.

    Boruzu — Initial Therapy

    Boruzu covered when ALL of the following are met:

    Boruzu criteria: 1) Medical records supporting the request provided including documentation of prior therapies and responses; AND 2) Step therapy: patient has tried and failed one generic bortezomib injectable product (e.g., HCPCS J9049 or J9041) prior to Boruzu;

    Coverage duration up to 1 year; dose per FDA labeling.

    Bosaya — Initial Therapy

    Bosaya covered when ALL of the following are met:

    Bosaya criteria: 1) Medical records supporting the request provided including prior therapies and responses; AND 2) Step therapy: patient has tried Jubbonti, Enoby, AND Bildyos prior to Bosaya;

    Coverage duration up to 2 years; dose per FDA labeling.

    Casgevy — Gene therapy initial criteria for SCD and Beta Thalassemia (including transfusion-dependence thresholds)

    Casgevy (gene therapy) covered when ALL of the following are met depending on indication:

    Casgevy SCD criteria: Sickle Cell Disease pathway: medical records provided AND genetic confirmation of SCD genotype (βS/βS, βS/β0, or βS/β+) AND history of ≥2 severe vaso‑occlusive events per year in the previous 2 years despite appropriate supportive care AND current weight provided AND adequate organ function and HSCT eligibility documented AND no contraindication to any product/procedure required for gene therapy AND trial and failure of hydroxyurea (or intolerance) plus at least one other SCD therapy if hydroxyurea not tolerated.>=2 severe VOC/yr

    Age ≥12 years; prescriber hematologist; authorization 6 months; one lifetime dose limit; excluded if prior HSCT or prior gene therapy.

    Casgevy Beta thalassemia criteria: Transfusion‑dependent beta thalassemia pathway: medical records provided AND history meeting transfusion‑dependence threshold (≥100 mL/kg/year OR ≥10 units/year pRBC in prior 2 years) AND no known/available HLA matched donor as determined by hematologist/transplant specialist AND provider attestation patient would be clinically stable and eligible for HSCT absent donor;>=100 mL/kg/yr or >=10 units/yr

    Age ≥12 years; prescriber hematologist; authorization 6 months; one lifetime dose limit; excluded if prior HSCT or prior gene therapy.

    Cimzia — Initial Therapy

    Covered when ALL of the following are met:

    Cimzia coverage criteria: 1) Medical records supporting the request and documentation of prior therapies and responses provided; AND 2) Prescriber is a specialist or has consulted with a specialist; AND 3) Step therapy: failure (intolerance or inadequate response) of TWO listed agents (preferred adalimumab product, Rinvoq, Skyrizi, Tyenne, Cosentyx, Otezla, Xeljanz/XR, Yesintek/Selarsdi, or Enbrel) prior to Cimzia; AND 4) Not used in combination with other biologic drugs, Otezla, or JAK inhibitors.

    Coverage duration 2 years; dose per FDA labeling or accepted standards.

    Cinqair and Severe eosinophilic asthma — initial and reauthorization criteria

    Covered when ALL of the following are met:

    Cinqair coverage criteria: 1) Medical records supporting the request provided, including prior therapies and responses; AND 2) Patient's current weight provided; AND 3) For initial coverage of severe eosinophilic asthma: blood eosinophil count ≥150 cells/mcL at therapy start OR ≥300 cells/mcL in the previous 12 months; AND 4) Step therapy: patient has tried and failed 1 ICS/LABA plus one other asthma controller medication in the past 6 months (failure defined as intolerance or inability to improve on therapy for at least 4 weeks).>=150 cells/mcL at start OR >=300 cells/mcL prior 12 months

    Prescriber is a specialist or has consulted with a specialist; reauthorization requires documented clinical benefit (decreased exacerbations, improved symptoms, or reduced oral steroid use).

    Cinryze — Initial Therapy/Step therapy

    Covered when ALL of the following are met

    Cinryze criteria: 1) Use is for a medically accepted indication not otherwise excluded; 2) Medical records supporting the request provided including documentation of prior therapies and responses; 3) Step therapy: patient has tried Haegarda prior to Cinryze approval;

    Coverage duration 2 years; dose per FDA labeling or accepted standards.

    anti-AAVrh74 titer (Elevidys)
    Total binding antibody titer <1:400 required for Elevidys patient selection.
  1. Beizray/Beizray‑Albumin: documentation that generic docetaxel (Taxotere, J9171) was tried prior to Beizray.
  2. Benlysta IV: SELENA‑SLEDAI ≥6 and either anti‑dsDNA >30 IU/mL or ANA >1:80 for SLE; kidney biopsy class 3,4, or 5 for lupus nephritis; specialist prescriber or consultation.
  3. Cimzia: medical records documenting failure of two listed prior agents and specialist prescriber/consultation.
  4. Cinqair: medical records including prior therapies, current weight, and eosinophil count ≥150 cells/mcL at start or ≥300 cells/mcL in prior 12 months.
  5. Prior Authorization

    PA duration and reauthorization expectations — typical 1 year initial; many reauth to 2 years

    Initial prior authorizations are typically granted for approximately 1 year (many reauthorizations up to 2 years); some products have shorter or lifetime limits — submit reauthorization documentation showing clinical benefit per product rules.

    • Initial approvals commonly 1 year; many reauthorizations are for 2 years (verify product‑specific duration).
    • Some agents have unique limits (e.g., Emblaveo approvals limited to 6 months; Casgevy authorization 6 months with one lifetime dose).
    • Ensure reauthorization requests include documentation of clinical benefit compared to baseline as required by the product (e.g., Amvuttra, Enjaymo, Elevidys).
    Denial Risk

    Denial risk — missing prior trials, diagnostic/genetic/antibody tests, or prohibited combinations

    Prior authorization requests lacking required prior‑trial evidence, diagnostic/antibody/genetic test results, or showing use with excluded combination therapies may be denied.

    • Missing documentation of required prior trials (e.g., hydroxyurea for Adakveo; Mvasi and Zirabev for Avastin; generic docetaxel for Docivyx) risks denial.
    • Absent diagnostic or lab criteria (e.g., SELENA‑SLEDAI and autoantibodies for Benlysta; anti‑AAVrh74 titer and DMD genotype for Elevidys) can trigger denial.
    • Requests for drugs used in prohibited combinations (e.g., Benlysta with another biologic or Lupkynis) may be denied as exclusions apply.
    Denial Risk

    Noncoverage triggers — Evenity and prohibited combinations

    Do not request coverage for products with explicit noncoverage triggers (example: Evenity cumulative use >12 months per lifetime) or for uses excluded by policy — such requests will be denied.

    • Evenity: cumulative use beyond 12 months per lifetime is not covered.
    • Products that must not be used in combination with excluded agents (e.g., Cosentyx IV, Entyvio) will be denied if combination use is documented.
    Documentation Required

    Required supporting records/tests — Emblaveo, Elevidys, Enjaymo, Encelto

    Attach the required medical records and test results listed per product: cultures and sensitivities or suspected organisms for Emblaveo; genotype confirmation and anti‑AAVrh74 titer for Elevidys; anti‑AAVrh74 <1:400; weight, baseline hemoglobin and transfusion history for Enjaymo; IS/OS PR (EZ) break and BCVA for Encelto.

    • Emblaveo: culture and sensitivity results or specified suspected organism(s); prescriber must be or consult an infectious disease specialist.
    • Elevidys: genetic confirmation of DMD excluding deletions in exon 8 or 9 and anti‑AAVrh74 total binding antibody titer <1:400; specialist prescriber or consultation required.
    • Enjaymo: current weight, baseline hemoglobin, confirmed CAD diagnosis, and documentation of at least one transfusion within 6 months prior to therapy.
    • Encelto: fluorescein angiography or OCT supporting MacTel type 2 diagnosis, IS/OS (EZ) break between 0.16 and 2.00 mm2, and BCVA ≥54 ETDRS letters; one implant per eye lifetime; approval limited to 6 months.
    Note

    Site‑of‑care and Part B administration — no explicit restrictions; follow Part B rules

    Follow Part B administration rules for site of care — there are no explicit site‑of‑care restrictions in the policy; drugs may be administered in infusion center, hospital outpatient, or office settings as applicable and billing should follow Part B processes.

    • No explicit site‑of‑care restrictions stated; administer per Part B rules.
    • Use the Medicare Part B drug request form/Web Form to document place of administration for billing and Part B vs Part D determinations.
    anti‑AAVrh74 antibody titer for Elevidys
    Anti‑AAVrh74 total binding antibody titer must be <1:400 for Elevidys initial eligibility and reauthorization checks.